AUSTRALIAN PRODUCT INFORMATION – SOLONE (PREDNISOLONE) TABLET

1 NAME OF THE MEDICINE
Prednisolone

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Prednisolone occurs as white to practically white, odourless, crystalline powder. Prednisolone is very slightly soluble in water and sparingly soluble in alcohol.

Solone tablets contain the following excipients; Lactose monohydrate, propyl hydroxybenzoate, gelatin, maize starch, wheat starch and magnesium stearate.

Excipient with known effect:
Lactose monohydrate, hydroxybenzoates.

3 PHARMACEUTICAL FORM
Tablet, uncoated.

Prednisolone (Solone) 5 mg tablet – White, round, biconvex, breakline on one side and marking ‘L’ on other side.

Prednisolone (Solone) 25 mg tablet – White, round, biconvex, breakline on one side and plain on other side scored.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
Wherever corticosteroid therapy is indicated.

4.2 DOSE AND METHOD OF ADMINISTRATION

Adults: 10 to 100 mg daily in divided doses.

Children: 1 to 5 years: 2.5 to 10 mg twice daily.

6 to 12 years: 5 to 20 mg twice daily.

4.3 CONTRAINDICATIONS
Systemic fungal infections and known hypersensitivity to prednisolone or any of the excipients.

Peptic ulcer, osteoporosis, psychoses or severe psychoneuroses. Patients with active or doubtfully quiescent tuberculosis should not be given these hormones except as adjuncts to treatment with tuberculostatic drugs.
4.4 **Special Warnings and Precautions for Use**

Corticosteroids should be used with caution in the presence of diminished cardiac reserve or congestive heart failure, in patients with diabetes mellitus, infectious diseases, chronic renal failure, uraemia and in elderly persons.

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunsuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.

**Scleroderma renal crisis**

Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more prednisolone. Blood pressure and renal function (s-creatinine) should therefore be routinely checked. When renal crisis is suspected, blood pressure should be carefully controlled.

**Withdrawal symptoms**

During prolonged treatment with corticosteroids, adrenal suppression and atrophy may occur and secretion of corticotrophin may be suppressed. Sudden withdrawal of the hormone treatment may then precipitate acute adrenal insufficiency with muscle weakness, hypotension, hypoglycaemia, headache, nausea, vomiting, restlessness and muscle and joint pain. Muscle weakness and stiff joints may persist for three to six months after treatment has been discontinued. In some instances, withdrawal symptoms may stimulate a clinical relapse of the disease for which the patient has been under treatment. Duration of treatment and dosage appear to be important factors in determining suppression of the pituitary adrenal axis and response to stress on cessation of steroid treatment. Individual liability to depression is also variable. Some patients may recover normal function rapidly. In others, the production of hydrocortisone in
response to the stress of infections, surgical operations or accident may be insufficient, and death results. Withdrawal of corticosteroids should therefore always be gradual but if sudden withdrawal is necessary, corticotrophin (20 units) given daily by intravenous infusion over eight hours for three to five successive days is usually sufficient to prevent withdrawal symptoms.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Steroids should be used with caution in non-specific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Since concurrent use of these agents results in a mutual inhibition of metabolism, it is possible that adverse events associated with the individual use of either drug may be more apt to occur.

**Visual disturbance**

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Use in the elderly
Corticosteroids should be used with caution in elderly persons.

Paediatric use
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Effects on laboratory tests
Glucocorticoids may decrease $^{131}$I uptake and protein-bound iodine concentrations, making it difficult to monitor the therapeutic response of patients receiving the drugs for thyroiditis. Glucocorticoids may produce false-negative results in the nitroblue tetrazolium test for systemic bacterial infection. Glucocorticoids may suppress reactions to skin tests.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS
The following drug interactions with corticosteroids have been selected on the basis of their potential clinical significance: antacids, antidiabetic agents (oral or insulin), digitalis glycosides, diuretics, drugs which induce hepatic microsomal enzymes, such as barbiturates, phenytoin and rifampicin; potassium supplements, ritodrine, sodium-containing medications or foods, somatrem or somatropin, vaccines, live viruses or other immunizations.

Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.

Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.

The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

4.6 FERTILITY, PREGNANCY AND LACTATION
Effects on fertility
No data available

Use in pregnancy – Pregnancy Category A
In animal experiments, corticosteroids have been found to cause malformations of various kinds (cleft palate, skeletal malformations) and abortion. These findings do not seem to be relevant to humans. Reduced placental and birth weight have been recorded in animals and humans after long term treatment. Since the possibility of suppression of the adrenal cortex in the newborn infant after long-term treatment must be considered, the needs of the mother must be carefully
weighed against the risk to the fetus when prescribing these drugs. The short-term use of corticosteroids antepartum for the prevention of respiratory distress syndrome does not seem to pose a risk to the fetus or the newborn infant. Maternal pulmonary oedema has been reported with tocolysis and fluid overload.

**Use in lactation.**

The drug is excreted in breast milk; therefore, administration to nursing mothers is not recommended.

### 4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

### 4.8 Adverse Effects (Undesirable Effects)

The side effects associated with the use of corticosteroids in the large doses necessary to produce a therapeutic response result from excessive action on electrolyte balance: excessive action on other aspects of metabolism including gluconeogenesis; the action on tissue repair and healing; and an inhibitory effect on the secretion of cortico-trophin by the anterior pituitary gland. Disturbance of electrolyte and water balance is manifest in sodium retention with oedema and hypertension, and in the increased excretion of potassium with the development of hypokalaemic alkalosis. In extreme cases cardiac failure may be induced. Disturbances of electrolyte balance are common with the naturally occurring corticotrophins, cortisone, deoxycortone and hydrocortisone but are less frequent with the synthetic derivatives, prednisone and prednisolone. Other metabolic effects include mobilisation of calcium and phosphorus with osteoporosis and spontaneous fractures; nitrogen depletion and hyperglycaemia with accentuation or precipitation of the diabetic state. The insulin requirements of diabetic patients are increased and appetite is often increased.

The effect on tissue repair manifests as peptic ulceration with haemorrhage and perforation, delayed wound healing and increased liability to infection. Increased susceptibility to all kinds of infection, including sepsis, fungal and viral infection, has been reported.

Large doses of corticosteroids or corticotrophins may produce symptoms typical of hyperactivity of the adrenal cortex, with moonface, buffalo hump, flushing, striae and acne sometimes leading to a fully developed Cushing's syndrome. If administration of the hormone is discontinued immediately on the appearance of these symptoms, they are usually reversed but such sudden cessation may be dangerous. The dose of corticosteroid required to cause a decrease or absence of corticotrophin in the blood with consequent atrophy of the adrenal cortex and the time required for its occurrence are very variable. Acute adrenal insufficiency with loss of consciousness may occur during prolonged treatment or on cessation of treatment and may be precipitated by an infection or trauma.

Growth retardation in children has been reported and in this respect cortisone is only one-tenth as potent as prednisone and prednisolone. Other toxic effects include mental and neurological disturbances, intracranial hypertension and, on sudden reduction of dosage during the treatment of rheumatoid arthritis, fatalities attributed to lesions of small arteries and arterioles similar to polyarteritis.
Infections may be masked since corticosteroids have marked anti-inflammatory and antipyretic properties and may produce a feeling of well-being. The administration of corticosteroids may also cause a reduction in the number of circulating lymphocytes.

Muscular weakness is an occasional side effect of most corticosteroids, particularly when they are taken in large doses.

Toxic effects occur with all corticosteroid preparations and their incidence rises steeply if dosage increases much above 8 mg daily of prednisolone or its equivalent.

**Scleroderma renal crisis**

Frequency ‘unknown’.

Amongst the different subpopulations the occurrence of scleroderma renal crisis varies. The highest risk has been reported in patients with diffuse systemic sclerosis. The lowest risk has been reported in patients with limited systemic sclerosis (2%) and juvenile onset systemic sclerosis (1%).

**FLUID AND ELECTROLYTE DISTURBANCES**

Sodium retention

Fluid retention

Congestive heart failure in susceptible patients. Potassium loss

Hypokalemic alkalosis

Hypertension

**MUSCULOSKELETAL**

Muscle weakness

Steroid myopathy

Loss of muscle mass

Osteoporosis

Tendon rupture, particularly of the Achilles tendon

Vertebral compression fractures

Aseptic necrosis of femoral and humeral heads

Pathologic fracture of long bones

**GASTROINTESTINAL**

Peptic ulcer with possible perforation and hemorrhage

Pancreatitis

Abdominal distention

Ulcerative oesophagitis
Increases in alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

**DERMATOLOGIC**
Impaired wound healing
Thin fragile skin
Petechiae and ecchymoses
Facial erythema
Increased sweating. May suppress reactions to skin tests

**METABOLIC**
Negative nitrogen balance due to protein catabolism

**NEUROLOGICAL**
Increased intracranial pressure with papilloedema (pseudo-tumour cerebri) usually after treatment
Convulsions
Vertigo
Headache

**ENDOCRINE**
Menstrual irregularities
Development of Cushingoid state
Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress as in trauma, surgery or illness. Suppression of growth in children
Decreased carbohydrate tolerance
Manifestations of latent diabetes mellitus
Increased requirements for insulin or oral hypoglycaemic agents in diabetics

**OPHTHALMIC (EYE DISORDERS)**
Posterior sub-capsular cataracts
Increased intraocular pressure
Glaucoma
Exophthalmos
Vision blurred

**ADDITIONAL REACTIONS**
Urticaria and other allergic, anaphylactic or hypersensitivity reactions
Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

Treatment There is no specific antidote. Toxic effects are signs of overdosage, and should be treated symptomatically and dosage reduced or the drug withdrawn. During long courses of treatment laboratory and metabolic studies should be made. Fluid retention should be watched for via a fluid balance chart and daily weighing. Sodium intake may need to be reduced to less than 1g daily and potassium supplements may be necessary.

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Prednisolone is a synthetic corticosteroid with glucocorticoid and anti-inflammatory effects. Prednisolone exceeds hydrocortisone in glucocorticoid and anti-inflammatory activity, being about three times more potent on a weight basis than the parent hormone, but is considerably less active than hydrocortisone in mineralocorticoid activity.

Prednisolone like hydrocortisone is a potent therapeutic agent influencing the biochemical behaviour of most tissues of the body.

The mechanism of action of corticosteroids is thought to be by control of protein synthesis. Corticosteroids react with receptor proteins in the cytoplasm of sensitive cells in many tissues to form a steroid-receptor complex.

Corticosteroids are palliative symptomatic treatment by virtue of their anti-inflammatory effects; they are never curative.

Clinical trials

No data available

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Prednisolone is readily absorbed from the gastrointestinal tract.

The plasma half-life after oral administration of prednisolone ranges from 3 to 4 hours. Oral bioavailability varies widely between subjects. Peak plasma concentrations of prednisolone are obtained 1 or 2 hours after oral administration and prednisolone has a usual plasma half-life of 2 to 4 hours. Its initial absorption, but not its overall bioavailability, is affected by food.
**Distribution**
Prednisolone is 90 to 95% bound to plasma proteins.

**Metabolism**
Prednisolone is conjugated in the liver and to some extent in the kidney.

**Excretion**
Prednisolone is excreted in the urine as free and conjugated metabolites, together with an appreciable proportion of unchanged prednisolone. Prednisolone crosses the placenta and small amounts are excreted in breast milk.

**5.3 Preclinical safety data**

**Genotoxicity**
In male rats, administration of prednisolone in the drinking water at a daily dose level of 0.4mg/kg for two years caused an increased incidence of hepatocellular tumours. Similar results were obtained with triamcinolone acetonide and budesonide, indicating a class effect of glucocorticosteroids. The hepatocarcinogenic response to these drugs does not appear to be related to genotoxic activity.

**Carcinogenicity**
The carcinogenic potential of prednisolone has been evaluated in mice at oral doses up to 5mg/kg/day for 18 months. No carcinogenic effect was noted in the mouse.

**6 Pharmaceutical particulars**

**6.1 List of excipients**
Refer to Section 2 - Qualitative and quantitative composition.

**6.2 Incompatibilities**
Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

**6.3 Shelf life**
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

**6.4 Special precautions for storage**
Store below 30°C. Protect from light.

**6.5 Nature and contents of container**
Supplied in HDPE bottles.
5mg tablet – 30’s#, 60’s, 100’s# and 1000’s# packs
25mg tablet – 30’s and 1000’s# packs
6.6 **SPECIAL PRECAUTIONS FOR DISPOSAL**

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 **PHYSICOCHEMICAL PROPERTIES**

   **Chemical structure**

![Chemical structure image]

Chemical name: 11β, 17α,21-Trihydroxypregna 1,4-diene-3,20-dione

   **CAS number**

50-24-8 (Anhydrous)

7 **MEDICINE SCHEDULE (POISONS STANDARD)**

S4 – Prescription Only Medicine

8 **SPONSOR**

iNova Pharmaceuticals (Australia) Pty Limited,
Level 10, 12 Help St,
Chatswood, NSW 2067

9 **DATE OF FIRST APPROVAL**

26 March 1997

10 **DATE OF REVISION**

22 October 2018

**SUMMARY TABLE OF CHANGES**

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Reformatted to new format</td>
</tr>
<tr>
<td>All</td>
<td>Updated to new format (March 2018)</td>
</tr>
<tr>
<td>Sections 4.4 &amp; 4.8</td>
<td>Safety-related request (SSR) – Inclusion of risk of visual disturbance and central serous chorioretinopathy (CSCR)</td>
</tr>
</tbody>
</table>